Pages that link to "Q1479804"

The following pages link to HIV vaccine (Q1479804):

Displayed 50 items.

• SAV001 (Q3381667) ‎ (← links)
• STEP Study (Q3592570) ‎ (← links)
• HIV Vaccine Trials Network (Q5629929) ‎ (← links)
• MVA-B (Q6719125) ‎ (← links)
• (Q11925975) ‎ (← links)
• The clinical development process for a novel preventive vaccine: An overview (Q26770871) ‎ (← links)
• Evaluating the efficacy of therapeutic HIV vaccines through analytical treatment interruptions (Q26777442) ‎ (← links)
• HIV/AIDS vaccines for Africa: scientific opportunities, challenges and strategies (Q26799624) ‎ (← links)
• Challenges in mucosal HIV vaccine development: lessons from non-human primate models (Q27022152) ‎ (← links)
• A global approach to HIV-1 vaccine development (Q27024614) ‎ (← links)
• Dendritic Cell-Based Immunotherapies to Fight HIV: How Far from a Success Story? A Systematic Review and Meta-Analysis (Q28070121) ‎ (← links)
• Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target (Q29547347) ‎ (← links)
• Immune-correlates analysis of an HIV-1 vaccine efficacy trial (Q29617377) ‎ (← links)
• Age and sex or gender (sex/gender) and HIV vaccine preparedness (Q30202232) ‎ (← links)
• Lessons from acute HIV infection (Q30490195) ‎ (← links)
• Stabilized HIV-1 envelope glycoprotein trimers for vaccine use. (Q30490942) ‎ (← links)
• HIV-1 group M conserved elements vaccine (Q33308246) ‎ (← links)
• HIV vaccine development in the aftermath of the STEP study: re-focus on occult HIV infection? (Q33366554) ‎ (← links)
• Lessons learned from human HIV vaccine trials (Q33557844) ‎ (← links)
• Use of nonhuman primate models to develop mucosal AIDS vaccines (Q33666002) ‎ (← links)
• "Rational vaccine design" for HIV should take into account the adaptive potential of polyreactive antibodies (Q33941047) ‎ (← links)
• Why HIV virions have low numbers of envelope spikes: implications for vaccine development (Q34016070) ‎ (← links)
• The role of follicular helper T cells and the germinal center in HIV-1 gp120 DNA prime and gp120 protein boost vaccination (Q34291205) ‎ (← links)
• Challenges in the design of a T cell vaccine in the context of HIV-1 diversity (Q34423446) ‎ (← links)
• Current progress in the development of a prophylactic vaccine for HIV-1. (Q34502108) ‎ (← links)
• Architectural insight into inovirus-associated vectors (IAVs) and development of IAV-based vaccines inducing humoral and cellular responses: implications in HIV-1 vaccines (Q34774808) ‎ (← links)
• Receptor binding domain based HIV vaccines. (Q35033862) ‎ (← links)
• HIV vaccine research: the challenge and the way forward (Q35227007) ‎ (← links)
• Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost (Q35760486) ‎ (← links)
• Can immunological principles and cross-disciplinary science illuminate the path to vaccines for HIV and other global health challenges? (Q35923859) ‎ (← links)
• HIV Vaccine: Recent Advances, Current Roadblocks, and Future Directions (Q36249933) ‎ (← links)
• Antibodyomics: bioinformatics technologies for understanding B-cell immunity to HIV-1. (Q36263513) ‎ (← links)
• Good CoP, bad CoP? Interrogating the immune responses to primate lentiviral vaccines (Q36356350) ‎ (← links)
• The changing face of HIV vaccine research (Q36404101) ‎ (← links)
• Towards a coronavirus-based HIV multigene vaccine (Q36502233) ‎ (← links)
• No vaccine against HIV yet--are we not perfectly equipped? (Q36580789) ‎ (← links)
• Development of prophylactic vaccines against HIV-1. (Q37042563) ‎ (← links)
• Recombinant Salmonella enterica serovar Typhimurium as a vaccine vector for HIV-1 Gag. (Q37235277) ‎ (← links)
• Epitope specificity of human immunodeficiency virus-1 antibody dependent cellular cytotoxicity [ADCC] responses (Q37426168) ‎ (← links)
• Progress toward active or passive HIV-1 vaccination (Q37549777) ‎ (← links)
• Combining biomedical preventions for HIV: Vaccines with pre-exposure prophylaxis, microbicides or other HIV preventions (Q37561407) ‎ (← links)
• Natural infection as a blueprint for rational HIV vaccine design (Q37619134) ‎ (← links)
• Native-like Env trimers as a platform for HIV-1 vaccine design (Q37633417) ‎ (← links)
• Ontogeny-based immunogens for the induction of V2-directed HIV broadly neutralizing antibodies (Q37634061) ‎ (← links)
• Lessons in AIDS vaccine development learned from studies of equine infectious, anemia virus infection and immunity (Q37666746) ‎ (← links)
• Modulation of HIV-1 immunity by adjuvants (Q37698564) ‎ (← links)
• HIV-1 vaccine immunogen design strategies (Q38330424) ‎ (← links)
• Applications of Gold Nanoparticles in Nanomedicine: Recent Advances in Vaccines. (Q38680785) ‎ (← links)
• Tet-On Systems For Doxycycline-inducible Gene Expression. (Q38842593) ‎ (← links)
• Polyvalent vaccine approaches to combat HIV-1 diversity (Q39108740) ‎ (← links)